Erbey Fatih, Bayram Ibrahim, Kuskonmaz Baris, Yilmaz Sema, Cetin Mualla, Uckan Duygu, Tanyeli Atila
Cukurova University Faculty of Medicine, Department of Pediatric Oncology & Pediatric Bone Marrow Transplantation Unit, Adana, Turkey.
Exp Clin Transplant. 2010 Sep;8(3):237-44.
We define the incidence, risk factors, and mortality rates for the occurrence of thrombotic microangiopathy in 50 children who underwent transplants between January 2006 and June 2008 at 2 Turkish pediatric centers.
The diagnosis of thrombotic microangiopathy was done according to the reports of International Working Group in 2007.
Fifty patients (27 male and 23 female; age range, 3 months to 18 years) were included. Patients with malignant and nonmalignant diseases were 13 (26%) and 37 (74%). Myeloablative and nonmyeloablative conditioning regimens were used in 29 (58%) and 21 patients (42%). Bone marrow was used as the source of stem cells in 32 patients (62%) and peripheral blood was used in 18 patients (36%). Thrombotic microangiopathy was seen in 3 of 50 cases (6%). Thrombotic microangiopathy developed in 3 of 18 patients in whom peripheral blood was used as the source of stem cells while none of 32 patients who had bone marrow as the source developed thrombotic microangiopathy (P < .05).
Using peripheral blood as a source of stem cells is a risk factor for development of thrombotic microangiopathy.
我们确定了2006年1月至2008年6月期间在2家土耳其儿科中心接受移植的50名儿童发生血栓性微血管病的发病率、危险因素和死亡率。
血栓性微血管病的诊断依据2007年国际工作组的报告进行。
纳入50例患者（男27例，女23例；年龄范围3个月至18岁）。患有恶性和非恶性疾病的患者分别为13例（26%）和37例（74%）。采用清髓性和非清髓性预处理方案的患者分别为29例（58%）和21例（42%）。32例患者（62%）使用骨髓作为干细胞来源，18例患者（36%）使用外周血。50例中有3例（6%）出现血栓性微血管病。在18例使用外周血作为干细胞来源的患者中有3例发生血栓性微血管病，而32例使用骨髓作为干细胞来源的患者均未发生血栓性微血管病（P<0.05）。
使用外周血作为干细胞来源是发生血栓性微血管病的一个危险因素。
